IFG Advisory’s Pacira BioSciences PCRX Stock Holding History

IFG Advisory’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.61K	Buy	+300	New	+$7.09K	﹤0.01%	1898

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IFG Advisory's PCRX Position: Q2 2026 in Review

IFG Advisory opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 300 shares worth $7.61K. The stake represents ﹤0.01% of the portfolio and ranks #1898 among its holdings.

253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

IFG Advisory held 300 shares of Pacira BioSciences worth $7.61K as of Q2 2026.
Pacira BioSciences was a new IFG Advisory position in Q2 2026.
Pacira BioSciences made up ﹤0.01% of IFG Advisory's portfolio in Q2 2026, its #1898 holding.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on IFG Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.